Dana-Farber Cancer Institute's Belfer Center announces Immuno-Oncology research collaboration with Array BioPharma

Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma. (NASDAQ: ARRY).

The research team at Dana-Farber’s Robert and Renée Belfer Center for Applied Cancer Science will work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to patients. The collaboration will leverage the Belfer Center’s proprietary immuno-oncology platform. Combining Dana-Farber’s oncology expertise with the Array’s proficiency in drug discovery provides a unique opportunity to accelerate drug discovery of effective medicines for patients with unmet medical need.

“We are very enthusiastic about working with Array to develop novel immune-oncology drugs because their team has a strong track record of drug discovery success yielding innovative cancer therapies. Together we have the potential to deliver novel molecules that target unique mechanisms to harness the immune system and result in durable efficacy,” said Kwok-Kin Wong, MD, PhD, scientific co-director of the Belfer Center for Applied Cancer Science and Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School.

“We are excited to partner with the Dana-Farber scientists at the Belfer Center. Their capabilities perfectly synergize with the capabilities and drug discovery track record of Array. Specifically, their expertise in target validation, pre-clinical models of immunotherapeutic activity and translational medicine will greatly enable Array’s ability to deliver innovative therapeutics in this area,” said Nick Saccomano, PhD, chief scientific officer, Array BioPharma.

Financial terms of the agreement are not being disclosed.